China revises GMPs
This article was originally published in The Tan Sheet
Executive Summary
China's State Food and Drug Administration proposes revised good manufacturing practices that would give nonprescription drug firms three years to implement changes once guidelines are issued. Guo Jingwu, director of drug safety in SFDA's Inspection Department, said June 2 at a conference in Shanghai that SFDA adopted the guidelines May 28 and expects to issue the document in June. China's Ministry Of Health is reviewing the guidance and will submit it to the World Trade Organization before releasing it. SFDA will give companies three years to implement changes, though firms that manufacture injection drugs and products on China's Essential Drug List will have two years. The GMP revision, a key goal for SFDA in 2010, is part of the agency's work to align China's pharmaceutical and medical device regulations with international standards (1"The Tan Sheet" March 8, 2010)
You may also be interested in...
China State FDA Includes Drug GMPs In Expected 2010 Reforms
China's State FDA insists it will align the country's pharmaceutical and medical device regulations with international standards. The question manufacturers have is, how soon
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.